Literature DB >> 31186890

Systemic targeted therapy beyond sorafenib.

Roniel Cabrera1.   

Abstract

Entities:  

Year:  2013        PMID： 31186890      PMCID： PMC6499302          DOI： 10.1002/cld.128

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  16 in total

Review 1.  Ras, PI(3)K and mTOR signalling controls tumour cell growth.

Authors:  Reuben J Shaw; Lewis C Cantley
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

2.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Authors:  Li Liu; Yichen Cao; Charles Chen; Xiaomei Zhang; Angela McNabola; Dean Wilkie; Scott Wilhelm; Mark Lynch; Christopher Carter
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

Review 3.  Role of tyrosine kinase inhibitors in cancer therapy.

Authors:  Amit Arora; Eric M Scholar
Journal:  J Pharmacol Exp Ther       Date:  2005-07-07       Impact factor: 4.030

4.  Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Cristine Allmer; James Thomas; Henry C Pitot; George Kim; Ross C Donehower; Tom Fitch; Joel Picus; Charles Erlichman
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

5.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

Authors:  Ghassan K Abou-Alfa; Lawrence Schwartz; Sergio Ricci; Dino Amadori; Armando Santoro; Arie Figer; Jacques De Greve; Jean-Yves Douillard; Chetan Lathia; Brian Schwartz; Ian Taylor; Marius Moscovici; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

Review 6.  Genomics and signaling pathways in hepatocellular carcinoma.

Authors:  Augusto Villanueva; Philippa Newell; Derek Y Chiang; Scott L Friedman; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2007-02       Impact factor: 6.115

7.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

8.  Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

Authors:  Melanie B Thomas; Jeffrey S Morris; Romil Chadha; Michiko Iwasaki; Harmeet Kaur; E Lin; Elinor Lin; Ahmed Kaseb; Katrina Glover; Marta Davila; James Abbruzzese
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

9.  Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

Authors:  Sandrine Faivre; Eric Raymond; Eveline Boucher; Jean Douillard; Ho Y Lim; Jun S Kim; Magaly Zappa; Silvana Lanzalone; Xun Lin; Samuel Deprimo; Charles Harmon; Ana Ruiz-Garcia; Maria J Lechuga; Ann Lii Cheng
Journal:  Lancet Oncol       Date:  2009-07-06       Impact factor: 41.316

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
View more
  1 in total

1.  Application of Trifluoroacetic Acid as a Theranostic Agent for Chemical Ablation of Solid Tissue.

Authors:  Samuel A Einstein; Emily A Thompson; Chunxiao Guo; Elizabeth M Whitley; James A Bankson; Erik N K Cressman
Journal:  J Vasc Interv Radiol       Date:  2019-09-16       Impact factor: 3.464
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.